US Patent Office To Determine Validity of UCB Patent

UCB

The US Patent and Trademark Office, or PTO, is set to begin a trial to determine whether or not UCB’s patent for an epilepsy drug is valid. The US based pharma company Argentum Pharmaceuticals is challenging the patent for UCB’s Vimpat drug. UCB released a statement saying that the company believed that the patent remains valid and that the patent will be upheld. Vimpat currently has sales of $758.7 million annually.

Read the source article at Reuters

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>